[ Price : $8.95]
FDA places a partial clinical hold on a Blueprint Medicines early-stage trial testing its experimental cancer drug because of safe...[ Price : $8.95]
Takeda says it is moving its narcolepsy Type 1 drug TAK-861 to a Phase 3 trial after reporting positive results from a Phase 2b tr...[ Price : $8.95]
FDA clears a Kenota Health 510(k) for its Kenota 1 Total IgE [immunoglobulin E] test system.[ Price : $8.95]
Federal Register notice: FDA debars Shanif Abdul Punjani for five years from importing or offering for import any drug into the U....[ Price : $8.95]
FDA extends by three months its review of a Regeneron supplemental BLA for Dupixent (dupilumab) as an add-on maintenance treatment...[ Price : $8.95]
Federal Register final rule: FDA issues a regulation to implement its authority to destroy a device valued at $2,500 or less that ...[ Price : $8.95]
Gilead Sciences says it will be discussing with FDA a failed confirmatory study of accelerated-approval Trodelvy (sacituzumab govi...[ Price : $8.95]
An FDA advisory committee briefing document reveals reviewer concerns about safety and efficacy issues in a Lykos Therapeutics NDA...